QuanDx   
QuanDx为个体化癌症治疗提供创新性的分子诊断

QuanDx Inc. was founded in September 2010. QuanDx’ vision is to develop and commercialize innovative and unique research / clinical diagnostic assays based on proprietary technology for use in clinical and research laboratories worldwide. Our patented technology is based on innovative Yin-Yang Probes which offer multiple benefits in the design and function of molecular based assays. The first commercial product will comprise of a multiplex assay that can detect 30 fusion genes in a single assay format. The ability to detect cancer specific fusion genes is important not only in cancer research, but also increasingly in clinical settings to ensure that correct diagnosis is made and the optimal personalized treatment is chosen. It is the objective of QuanDx to offer a simpler and cost-effective solution for the detection of these important fusion genes.